Health Canada OKs Custom-Fit CPAP Mask
'The medical device industry has long assumed that mass production and true personalization are incompatible. FormFit proves they are not.'
'The medical device industry has long assumed that mass production and true personalization are incompatible. FormFit proves they are not.'
A noninvasive treatment may safely stimulate brain toxin clearance via meningeal lymphatic vessels during wakefulness.
The Series B funding will be used to advance the clinical-stage med-tech company's neuromodulation therapy for obstructive sleep apnea.
A computer chip tested in people’s spines could provide a scalable approach to targeting multiple neurological regions and unlock new therapeutic opportunities for brain-computer interfaces and spinal cord stimulators.
Read MoreResearchers are developing an AI-powered brain implant that adapts in real time to control Parkinson’s symptoms, providing personalized relief for both movement challenges and insomnia.
Read MoreUC Berkeley researchers have created earpieces that identify brain activity associated with relaxation and drowsiness.
Read MoreResearchers at the facility aim to develop technologies for studying lucid dreaming and REM sleep phenomena.
Read MoreThe new COO joins StimAire to advance the development of its injectable neurostimulator for obstructive sleep apnea.
Read MoreThe funding will support the CEO’s vision to make lucid dreaming accessible to the masses.
Read MoreNeuroLight Inc developed a prototype of a sleep mask that uses light and sound for brain entrainment to improve sleep quality.
Read MoreThe FDA has agreed on the design for Nexalin’s planned clinical studies of the Gen-3 HALO Clarity, targeting insomnia and anxiety.
Read MoreNyxoah advances its US launch plans for the Genio system, which recently achieved positive co-primary endpoints in the DREAM US pivotal study.
Read MoreThe company is now boosting production to 500 units in anticipation of US clinical trials aimed at validating the device’s efficacy for at-home insomnia treatment.
Read MoreAlkermes plc announced positive results from a phase 1b study evaluating ALKS 2680 for treating narcolepsy type 2 and idiopathic hypersomnia.
Read MoreResearch involving 67 subjects who participated in over 7,772 sleep sessions demonstrated that 73% experienced notable improvements in their sleep, with enhancements in the depth and overall quality of sleep noted.
Read MoreResearchers tested technology that allows people to control a smart home from lucid dreams. As a result, these people completed some typical morning actions before even waking up.
Read MoreThe platform uses neurotechnology to read individual brainwaves and guide them in real time by responding with tailored stimulation.
Read MoreThe patent covers a novel method of facilitating a normal sleep cycle in a subject during a pandemic or peri-COVID vaccination period.
Read More